Characteristics of outpatients with COPD in daily practice: The E4 Spanish project  by Viejo-Bañuelos, José L. et al.
ARTICLE IN PRESSRespiratory Medicine (2006) 100, 2137–21430954-6111/$ - s
doi:10.1016/j.r
Correspondi
fax: +34 947 28
E-mail addrCharacteristics of outpatients with COPD in daily
practice: The E4 Spanish project
Jose´ L. Viejo-Ban˜uelosa,, Ana Pueyo-Bastidaa, Arturo Fueyo-Rodrı´guezbaService of Pneumology, Hospital General Yagu¨e, Avenida Cid 96, E-09005 Burgos, Spain
bMedical Department, GlaxoSmithKline, S.A., Tres Cantos, Madrid, Spain
Received 12 April 2005; accepted 20 March 2006KEYWORDS
Chronic obstructive
pulmonary disease
(COPD);
Primary care;
Cigarette smoking;
COPD management;
Airﬂow limitationee front matter & 2006
med.2006.03.043
ng author. Tel.: +34 947
2805.
ess: jlviejo@hgy.es (J.LSummary The objective of this 1-week cross-sectional survey was to assess the
clinical features of outpatients with chronic obstructive pulmonary disease (COPD).
A one-page questionnaire was used to collect demographic data, smoking status, and
COPD-related variables. Ten or 20 consecutive patients were selected from Primary
care or specialised setting during a week. Pulmonary function (FEV1) was measured
using an electronic device (Piko-1). The study sample comprised 11,973 COPD
patients (83% men) with a mean (SD) age of 67 (10.7) years. Thirty-ﬁve percent of
patients were current smokers and smoked a mean of 17.4 (9.9) cigarettes daily.
COPD severity according to GOLD stages was mild in 20% of patients, moderate in
38%, severe in 30%, and very severe in 12%. A higher percentage of men showed
severe (33%) or very severe (14%) disease compared to women (16% and 6%,
respectively) (Po0.005). Forty-two percent of patients had severe functional
impairment and 35% continued smoking. Moreover, 11% of patients with very severe
COPD smoked more than 20 cigarettes a day. The mean frequency of visits in the
previous year was every 4.6 (4.1) months, with cough as the main reason for
consultation. The most commonly used drugs were long-acting b2-agonists (78%) and
inhaled steroids (77%). Inhaled steroids were used by 84% of patients with very
severe, 82% with severe disease, 73% with moderate disease, and 69% with mild
disease (w2 for trend, Po0.0001). This survey carried out in a real life setting shows
that 42% of the patients who completed the questionnaire had severe COPD, 35% of
them continued smoking, and 69% of patients with mild COPD used inhaled steroids.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
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. Viejo-Ban˜uelos).Introduction
Chronic obstructive pulmonary disease (COPD) is a
disabling condition associated with progres-
sive airﬂow limitation that is largely irreversible,
with symptoms of dyspnea, cough, and sputumed.
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COPD is a public health problem worldwide and a
major cause of chronic morbidity and mortality.
The 2002 WHO World Health Report1 listed COPD as
a ﬁfth leading cause of death in the world, and
further increases in its prevalence and mortality
are expected in the coming decades.2 This disease
is the most steeply rising cause of death in
individuals older than 65 years of age, which
represents the most rapidly growing segment of
the population in developed countries. Disability
from COPD is expected to rise by 2020 with aging of
the population and the increase in disease pre-
valence.3 In 2001, the Global Initiative for chronic
obstructive lung disease (GOLD) issued and now
updates yearly guidelines4 that aim to increase
awareness of COPD and to improve prevention and
management of this highly prevalent disease. On
the other hand, the GOLD project has emphasized
that COPD is a preventable and treatable condition
and has deﬁned global standards of care. However,
pharmacological therapy for COPD seems currently
not effective.4
Detailed information on the burden of COPD on
the patient, health care system, and the economy
has now become available from confronting COPD
in North America and Europe, the ﬁrst international
survey to quantify the country-speciﬁc impact of
the disease.5–8 An economic analysis of the results
of the Spanish survey9 revealed that annual cost of
COPD to the health care system was 3238 h per
patient, with inpatient hospitalization accounting
for almost 84% of the total direct cost of the
disease. As the major cause of inpatient hospitali-
zation for COPD is acute exacerbations, these
results highlight the need for interventions in the
outpatient setting to prevent exacerbations. The
impact of COPD on the health care system may also
be due to the underdiagnosis and treatment of
COPD, suggesting that costs may be reduced by
improving the diagnosis and treatment of the
disease in primary care. However, in order to offer
effective intervention strategies it is essential to
deﬁne the target population clearly and to have
information on the COPD patient’s proﬁle in a real
life setting. Therefore, this study was designed to
collect information on the clinical features of a
large sample of outpatients with COPD visited in
actual conditions of the daily practice.Methods
The E4 Spanish Project (‘‘Estudio Espan˜ol de
Evaluacio´n de la EPOC’’ or Spanish Study of the
Assessment of COPD) was a 1-week (8–18 March2004) cross-sectional survey of the ﬁrst 10 and 20
consecutive patients with COPD visited in the
outpatient setting by general practitioners and
pneumologists, respectively, from all over the
country in Spain. A sample of 1200 general
practitioners and 250 pneumologists were recruited
using a stratiﬁed random sample drawn from the
list of registered physicians. Physicians were
eligible for inclusion in the sampling frame if they
were actively practicing in Spain, reported spend-
ing at least 50% of their time in direct patient care
and had a primary specialty in family practice or
pneumology. Physicians participated voluntarily in
the study and did not receive any payment.
Patients were included in the study provided that
a previous diagnosis of COPD (conﬁrmed by history
and spirometry) had been established and that the
reason of consultation was related to his/her
pulmonary condition. Spirometric measurements
at the time of the study were not performed. For
the diagnosis of COPD recorded in the medical
record, subjects were required to present the
functional obstruction criteria of the European
Respiratory Society on spirometry,10 or in the case
of a positive bronchodilator test, values after the
challenge still had to fulﬁll the criteria for
bronchial obstruction. Patients with a previous
medical diagnosis of asthma, restrictive lung dis-
ease, bronchiectasis, cystic ﬁbrosis or pulmonary
ﬁbrosis according to clinical, spirometric and
radiological data were excluded. All patients gave
oral informed consent.
Interviews were carried out by the participating
physician in the course of the patient’s consultation
in routine daily practice using a questionnaire to
collect data on age and sex, smoking status, COPD
severity, frequency of medical visits, reason for
consultation, current symptoms, COPD-related stu-
dies performed in the previous 12 months, and
drugs (and number of agents) currently used for the
treatment of COPD (Table 1). The intensity of
clinical symptoms presented by the patient was not
evaluated. In respect to the smoking habit, a
marker of cumulative exposure, such as pack-years
was not recorded to facilitate fulﬁlment of the
questionnaire as much as possible due to the usual
workload conditions of general practices. Passive
smoking was deﬁned as the inhaling of environ-
mental tobacco smoke either at home or at the
workplace. Data regarding long-term oxygen ther-
apy were not collected because in the Spanish
health care system, COPD patients on long-term
oxygen therapy are usually visited at a more
specialized care level. The questionnaire was
developed ad hoc by us for this study. Pulmonary
function (forced expiratory volume in 1 s, FEV1) was
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Table 1 Questionnaire used in the survey.
Outpatients with COPD in daily practice 2139measured using an electronic device (Piko-1,
Ferraris Medical, Hertford, UK). This device was
provided by the sponsor. The Piko-1 device meets
American Thoracic Society (ATS) monitoring and
diagnostic device recommendations for accuracy in
the measurement of peak ﬂow rate and FEV1
11 and
has been recently validated.12
The severity of COPD was deﬁned according to
GOLD stages as mild, moderate, severe, and very
severe.4
The statistical tests performed were descriptive:
mean and SD. Differences of severity by gender, use
of inhaled corticosteroids by severity, and un-
treated patients by severity were compared by
w2-test.Results
A total of 865 general practitioners and 170
pneumologists participated in the study. A total of
14,084 questionnaires were collected; however2111 questionnaires were not included in the
analysis because of incomplete data or not accom-
plishing selection criteria. So, the study population
included 11,973 COPD patients who fulﬁlled the
inclusion criteria and for which valid and complete
data were collected A total of 83% of patients were
men, with a mean age (SD) of 67 (10.7) years.
Regarding the age, 46% of patients were ranged
between 56 and 70 years old and 40% of patients
were older than 70 years old. Anthropometric data
included a mean (SD) weight of 76.0 (12.7) kg and a
mean (SD) height of 165.7 (7.5) cm.
COPD severity was graded as mild in 20% of
patients (n ¼ 2395), moderate in 38% (n ¼ 4484),
severe in 30% (n ¼ 3618), and very severe in 12%
(n ¼ 1476).
Statistically signiﬁcant differences in COPD se-
verity between males and females was found.
A higher percentage of men showed severe (33%)
or very severe (14%) disease compared to women
(16% and 6%, respectively); in contrast, 41% of
women had mild COPD compared with 15% of men
(w2-test, Po0.001 in all comparisons).
Thirty-ﬁve percent of patients (n ¼ 4146) were
current smokers, 54% exsmokers (n ¼ 6473), and
11% never smokers (n ¼ 1354). Current smokers
smoked a mean of 17.4 (9.9) cigarettes daily, and
ex-smokers stopped smoking for a mean of 9.8 (8.1)
years. The percentage of non-smokers was 4% in
men compared with 37% in women. However, the
percentage of current smokers was 35% both in men
and women. Passive smoking was recorded in 38% of
ex-smokers or never smokers; 43% of women were
considered as passive smokers compared with 29%
of men. In Fig. 1 is represented the smokers and
severity.
In the group of 6473 ex-smokers, the time elapsed
from smoking cessation ranged between 6 and 10
years in 26% of patients and was longer than 10 years
in 29%. The mean frequency of medical visits was
every 4.6 (4.1) months (range 3.7–7.1 months), with
a slightly shorter interval for patients with severe
COPD than for patients with mild severity (4.7 [4.0]
vs. 4.1 [3.6] months). The main reasons of consulta-
tion are depicted in Fig. 2. These ﬁgures are related
to the presenting symptoms whether they were
unique or not. In patients with very severe COPD,
dyspnea was the reason to seek medical care in 50%
of patients, whereas in patients with moderate or
mild COPD, cough was the main reason (about 44% of
patients). With regard to clinical symptoms, 64% of
patients presented with cough, 54% with dyspnea,
50% with expectoration, and 15% with an acute
exacerbation episode. There were no substantial
differences in the distribution of symptoms accord-
ing to severity stages.
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Figure 1 Distribution of 4146 current smokers according to severity of COPD (very severe, n ¼ 394; severe, n ¼ 1140;
moderate, n ¼ 1670; mild, n ¼ 942) and daily consumption of cigarettes.
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Figure 2 Percentage of patients according to reason for consultation.
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performed in 69% of patients, chest radiography
in 60%, blood gases/pulse oximetry in 34%, standard
blood tests in 2%, and none of these in 15%. As
expected, the percentage of patients undergoing
spirometry, chest X-rays, and blood gases/pulse
oximetry was higher in very severe and severe
stages than in moderate and mild COPD (Fig. 3).
Sixty-nine percent of patients were treated with
short-acting bronchodilators (anticholinergics 29%,
b2-agonists 40%); 61% with long-acting bronchodi-
lators (anticholinergics 37.6%, b2-agonists 23.5%),
22% with inhaled steroids, 55% with a ﬁxed
combination of inhaled steroids and long-acting
b2-agonists (for description purposes, the ﬁxed
combination is considered as a single agent), 3%
with oral steroids and 5% with theophylline. A total
of 39% were treated with a combination of twodrugs (mainly long-acting anticholinergic agents
plus a ﬁxed combination of inhaled steroids and
long-acting b2-agonist), and 36% with a three-drug
combination (mainly long-acting anticholinergic
agents plus short-acting b2-agonists plus a ﬁxed
combination of inhaled steroids and long-acting b2-
agonist).
With regard to the use of inhaled steroids
according to COPD severity, 84.4% of patients with
very severe disease received inhaled steroids,
81.6% of patients with severe disease, 73.4% of
patients with moderate disease, and 69% of
patients with mild disease (w2, Po0.0001). It was
observed that inhaled steroids were used by a large
percentage of patients with mild disease. On the
other hand, 1.9% of patients with very severe
COPD, 1.3% with severe COPD, and 2.8% with
moderate COPD did not receive drug treatment,
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Figure 3 Percentage of patients undergoing different investigational studies in the previous 12 months according to
severity of COPD.
Outpatients with COPD in daily practice 2141which was signiﬁcantly different that the percen-
tage of 6.7% of untreated patients with mild COPD
(Po0.05).Discussion
A recent European Respiratory Society survey has
reported that COPD affects 4.6% of adults in
Europe.13 The clinical, human, and economic costs
of COPD are vast.2 In spite of this, COPD is
neglected for many clinicians, researchers, and
health care planners,14 who have a tendency to
view this disease as self-inﬂicted (by smoking) and
untreatable due to an extreme shortage of viable
treatment options. COPD medications relieve
symptoms, but are not curative in any way or
combination, and their effectiveness also di-
minishes over time. Moreover, some treatments
administered to patients with COPD are not
adequate for the degree of severity of the disease
and do not always follow current guidelines. A
further important aspect is the lack of knowledge
that many patients have of the disease. Patients at
an early stage of the disease are either unaware of
their condition or reluctant to consult their
physician for respiratory symptoms.15 Conse-
quently, most patients with mild disease do not
receive active counselling against tobacco smoking
or appropriate pharmacological treatment.
In agreement with these issues, the present study
carried out in the outpatient setting and in a large
number of patients, in whom the diagnosis of COPD
had been previously established, shows that 42% ofpatients presented with severe COPD. The high rate
of patients with severe COPD may be explained by
the study design; this was not a population-based
study and the study sample was drawn from
patients attending the outpatient clinics, thus it
is likely that patients with more severe respiratory
dysfunction are expected to seek medical care.
Because intensity of clinical symptoms was not
recorded, no inferences can be made regarding the
possibility of a discrepancy between the intensity
of manifestations, particularly cough and breath-
lessness, and the patient’s own assessment of
severity of disease. One of the interesting conclu-
sions from the Confronting COPD International
Survey5 is that subjects with COPD underestimate
their morbidity, as evidenced by a high proportion
of subjects with limitations in daily life activities, a
marked loss of work, and frequent use of health
services. On the other hand, 10% and 12% of
patients with very severe and severe COPD had no
tests performed in the previous 12 months and less
than 50% of patients with severe disease had
undergone analysis of blood gases and/or pulse
oximetry. Other epidemiological studies have docu-
mented the reduced percentage of COPD patients
having lung function testing. Marco Jordan et al.16
found that only 25% of their patients with COPD had
had a previous spirometry. In a survey on primary
care in Spain, Miravitlles et al.17 found that only
47% of patients treated and followed up because of
chronic respiratory symptoms had spirometry per-
formed.
Regarding treatment, another ﬁnding of this
survey is that almost 70% of the subjects reported
use of inhaled bronchodilators, a percentage
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Confronting COPD International Survey.5
In the current study, females represented 17% of
the COPD subjects, which is similar to 22% found in
the IBERPOC multicenter epidemiological study also
carried out in our country.18 Females reported a
different smoking history than males: 25% of
women were ex-smokers compared with 60% of
men, and 37% of women never smoked compared
with 4% of men. In the IBERPOC study,18 marked
differences were observed between sexes in smok-
ing: the percentage of nonsmokers was 23% in men
and 76.3% in women. Moreover, in this study,
passive smoking was recorded in 43% of females
and only in 29% of males. However, the percentage
of current smokers (35%) was similar in both
genders, despite the fact that 41% of women had
mild COPD compared with 15% of men. A remark-
able ﬁnding was that 11% of smoker patients with
very severe COPD smoked more than 20 cigarettes a
day. Therefore, efforts at preventing the initiation
of tobacco smoking and interventions directed to
quit smoking seems to be of utmost importance.
Targeting smoking cessation programs in women
with COPD are also necessary because it has been
shown that women who smoke have greater
difﬁculty quitting than men.19,20 On the other
hand, increases in the prevalence of COPD have
been observed in women of all ages in the UK,
which is in contrast with a plateau observed in the
prevalence of COPD in men from the mid 1990s.21
This trend, together with the ageing of the
population and the long term cumulative effect of
pack-years of smoking in women, is likely to further
increase the present burden of COPD.22,23
With regard to the use of spirometric screening in
early detection of COPD, a Polish experience on
11,027 smokers of439 years with a smoking history
of410 packyears, showed that spirometric signs of
airway obstruction were found in 24.3% of screened
subjects.24 This research group also was able to
demonstrate in a subgroup of screened smokers
that, after a minimal antismoking intervention,
those with abnormal lung function had double
quitting rate at 1 year compared with those with
normal spirometry.25 In this respect, measurements
of FEV1 or peak ﬂow rate using a portable
electronic device as that used in our study
incorporated into clinical consultation may be very
useful not only for COPD screening but also to
strength the physician’s advice to quit smoking in
patients even without signs of airﬂow impairment.
The present results should be interpreted ac-
cording to limitations related to the cross-sectional
design of the study. Therefore, variation in the
prevalence of COPD cannot be assessed nor theeffect of other risk factors different than smoking.
In contrast, the use of a brief, 1-page study
questionnaire facilitated physicians’ acceptance
to take part in the study and the recruitment of a
large number of patients in real conditions of the
daily practice, according to which it has been
possible to deﬁne the salient characteristics of
outpatients with COPD.
In summary, the present ﬁndings in a large
sample of 11,973 outpatients with COPD attended
in the outpatient setting indicate that 42% of
patients had severe functional impairment and
that 35% of patients continued smoking. Moreover,
11% of patients with very severe COPD smoked
more than 20 cigarettes a day. Intervention
strategies directed to quit smoking are urgently
needed.Acknowledgments
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